By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.

(Reuters) -Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...